BioVersys AG
BioVersys AG
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex | Acinetobacter Baumannii-calcoaceticus Complex; Colistin Resistanrt ABC; Hospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP) | Recruiting | Phase 3 | 2026-05-04 | NCT07326540 | |
| Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, Infections, Neuroinflammatory Diseases, Tuberculosis, Central Nervous System, Tuberculosis, Extrapulmonary, bacterial infectious disease, bacterial meningitis, central nervous system disorder, central nervous system infectious disorder, gram-positive bacterial infections, meningeal tuberculosis, meningitis, mycobacterial infectious disease, nervous system disorder, tuberculosis | Not yet recruiting | Phase 2 | 2026-03-03 | NCT07350174 | |
| Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex | Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, Cerebral Ventriculitis, Infections, Infectious Ventriculitis, Neuroinflammatory Diseases, bacterial infectious disease, bacterial meningitis, brain disorder, central nervous system disorder, central nervous system infectious disorder, encephalitis, meningitis, nervous system disorder, viral infection of central nervous system | Not yet recruiting | Phase 2 | 2026-02-24 | NCT07431307 |